国产三级日产三级韩国三级|暖暖日本在线观看|91自拍一区,成人免费黄色网站视频,97久久综合区小说区图片区,免费a视频

                              Today

                              2017-2020

                               

                               

                              To become innovation-driven enterprise, to build brand enterprise position in the industry, to become high-standard benchmarking enterprise of family used medicine. Chiral Pharmaceutical gains market reorganization in Europe and America.

                              In 2016

                               

                               

                              Joined Zhejiang Yongtai Technology Limited Liability Company

                              In 2014

                               

                               

                              Foshan Chiral Pharmaceutical Co., Ltd.

                              In 2005

                               

                               

                              Actavis (Foshan) Pharmaceutical Co., Ltd. 

                              In 2001

                               

                               

                              Alpharm(Foshan)pharmaceutial Co.,ltd

                              In 1994

                               

                               

                              Foshan Kangbaoshun Pharmaceutical Co., Ltd.

                              Joint-ventured by Foshan Pharmaceutical Plant, Foshan Youlian Medical Co., Ltd. and Australia Faulding Pharmaceutical Group

                               

                              In 1990

                               

                               

                              Foshan Youlian Medical Co., Ltd.

                              In 1958

                               

                               

                              Foshan Pharmaceutical Plant 

                              Copyright(C)2018,Foshan Chiral Pharmaceutical Co., Ltd. All Rights Reserved. Supported byChemNet?ChinaChemNet?Toocle?Copyright Notice